Neurocrine Other Liab from 2010 to 2024

NBIX Stock  USD 125.00  1.71  1.39%   
Neurocrine Biosciences Other Liabilities yearly trend continues to be fairly stable with very little volatility. Other Liabilities will likely drop to about 24.8 M in 2024. During the period from 2010 to 2024, Neurocrine Biosciences Other Liabilities regression line of annual values had r-squared of  0.04 and arithmetic mean of  22,208,348. View All Fundamentals
 
Other Liabilities  
First Reported
2000-03-31
Previous Quarter
29.7 M
Current Value
41.3 M
Quarterly Volatility
17.5 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 22.4 M, Interest Expense of 7.4 M or Selling General Administrative of 894.2 M, as well as many indicators such as Price To Sales Ratio of 6.48, Dividend Yield of 0.0 or PTB Ratio of 6.13. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Other Liab Growth Pattern

Below is the plot of the Other Liab of Neurocrine Biosciences over the last few years. It is Neurocrine Biosciences' Other Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Other Liab10 Years Trend
Pretty Stable
   Other Liab   
       Timeline  

Neurocrine Other Liab Regression Statistics

Arithmetic Mean22,208,348
Geometric Mean20,121,285
Coefficient Of Variation39.29
Mean Deviation6,799,791
Median22,567,000
Standard Deviation8,725,126
Sample Variance76.1T
Range30.1M
R-Value0.19
Mean Square Error79T
R-Squared0.04
Significance0.49
Slope373,587
Total Sum of Squares1065.8T

Neurocrine Other Liab History

202424.8 M
202334.2 M
202229.7 M
202112.3 M
20209.7 M
201917.1 M
201835.7 M

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Other Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Other Liabilities34.2 M24.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.